[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Download PDF
Table 1. Characteristics of the Study Population by Categories of PFOA Levela
Table 1. Characteristics of the Study Population by Categories of PFOA Levela
Table 2. Association Between Serum PFOA Level and the Presence of CVD or PAD
Table 2. Association Between Serum PFOA Level and the Presence of CVD or PAD
Table 3. Association Between Serum PFOA Level and the Presence of CVD or PAD by Sex
Table 3. Association Between Serum PFOA Level and the Presence of CVD or PAD by Sex
Table 4. Association Between Serum PFOA Level and the Presence of CVD or PAD by Smoking Status
Table 4. Association Between Serum PFOA Level and the Presence of CVD or PAD by Smoking Status
Table 5. Association Between Serum PFOA Level and the Presence of CVD or PAD by BMI Categories
Table 5. Association Between Serum PFOA Level and the Presence of CVD or PAD by BMI Categories
1.
US Environmental Protection Agency.  Perfluorooctanoic acid (PFOA) and fluorinated telomers. http://www.epa.gov/oppt/pfoa/. Accessed May 5, 2010
2.
Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. Perfluoroalkyl acids: a review of monitoring and toxicological findings.  Toxicol Sci. 2007;99(2):366-394PubMedArticle
3.
Cui L, Zhou QF, Liao CY, Fu JJ, Jiang GB. Studies on the toxicological effects of PFOA and PFOS on rats using histological observation and chemical analysis.  Arch Environ Contam Toxicol. 2009;56(2):338-349PubMedArticle
4.
Calafat AM, Wong LY, Kuklenyik Z, Reidy JA, Needham LL. Polyfluoroalkyl chemicals in the US population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000.  Environ Health Perspect. 2007;115(11):1596-1602PubMedArticle
5.
Olsen GW, Burris JM, Ehresman DJ,  et al.  Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers.  Environ Health Perspect. 2007;115(9):1298-1305PubMedArticle
6.
Levy RI, Moskowitz J. Cardiovascular research: decades of progress, a decade of promise.  Science. 1982;217(4555):121-129PubMedArticle
7.
Willett WC. Balancing life-style and genomics research for disease prevention.  Science. 2002;296(5568):695-698PubMedArticle
8.
Grundy SM, D’Agostino RB Sr, Mosca L,  et al.  Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood Institute workshop.  Circulation. 2001;104(4):491-496PubMedArticle
9.
Nieto FJ. Cardiovascular disease and risk factor epidemiology: a look back at the epidemic of the 20th century.  Am J Public Health. 1999;89(3):292-294PubMedArticle
10.
Bhatnagar A. Environmental cardiology: studying mechanistic links between pollution and heart disease.  Circ Res. 2006;99(7):692-705PubMedArticle
11.
Taylor AE. Cardiovascular effects of environmental chemicals.  Otolaryngol Head Neck Surg. 1996;114(2):209-211PubMedArticle
12.
Steenland K, Tinker S, Frisbee S, Ducatman A, Vaccarino V. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant.  Am J Epidemiol. 2009;170(10):1268-1278PubMedArticle
13.
Nelson JW, Hatch EE, Webster TF. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general US population.  Environ Health Perspect. 2010;118(2):197-202PubMedArticle
14.
Sakr CJ, Kreckmann KH, Green JW, Gillies PJ, Reynolds JL, Leonard RC. Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers.  J Occup Environ Med. 2007;49(10):1086-1096PubMedArticle
15.
Sakr CJ, Leonard RC, Kreckmann KH, Slade MD, Cullen MR. Longitudinal study of serum lipids and liver enzymes in workers with occupational exposure to ammonium perfluorooctanoate.  J Occup Environ Med. 2007;49(8):872-879PubMedArticle
16.
Olsen GW, Zobel LR. Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers.  Int Arch Occup Environ Health. 2007;81(2):231-246PubMedArticle
17.
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories.  Circulation. 1998;97(18):1837-1847PubMedArticle
18.
Lin CY, Chen PC, Lin YC, Lin LY. Association among serum perfluoroalkyl chemicals, glucose homeostasis, and metabolic syndrome in adolescents and adults.  Diabetes Care. 2009;32(4):702-707PubMedArticle
19.
Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study.  J Am Coll Cardiol. 2007;49(21):2112-2119PubMedArticle
20.
Steenland K, Tinker S, Shankar A, Ducatman A. Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with uric acid among adults with elevated community exposure to PFOA.  Environ Health Perspect. 2010;118(2):229-233PubMedArticle
21.
Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992.  JAMA. 2000;283(18):2404-2410PubMedArticle
22.
National Center for Health Statistics.  National Health and Nutrition Examination Survey: reference manuals and reports. http://www.cdc.gov/nchs/nhanes/nhanes2003-2004/nhanes03_04.htm. Accessed May 5, 2010
23.
Lang IA, Galloway TS, Scarlett A,  et al.  Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults.  JAMA. 2008;300(11):1303-1310PubMedArticle
24.
Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.  Circulation. 2004;110(6):738-743PubMedArticle
25.
American Diabetes Association.  Peripheral arterial disease in people with diabetes.  Diabetes Care. 2003;26(12):3333-3341PubMedArticle
26.
National Center for Health Statistics CfDC.  Laboratory procedure manual for serum creatinine. http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/l40_c_met_creatinine.pdf. Accessed May 6, 2010
27.
American Diabetes Association.  Diagnosis and classification of diabetes mellitus.  Diabetes Care. 2012;35:(suppl 1)  S64-S71PubMedArticle
28.
Chobanian AV, Bakris GL, Black HR,  et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.  Hypertension. 2003;42(6):1206-1252PubMedArticle
29.
Hanhijärvi H, Ophaug RH, Singer L. The sex-related difference in perfluorooctanoate excretion in the rat.  Proc Soc Exp Biol Med. 1982;171(1):50-55PubMed
30.
Harada K, Saito N, Inoue K,  et al.  The influence of time, sex and geographic factors on levels of perfluorooctane sulfonate and perfluorooctanoate in human serum over the last 25 years.  J Occup Health. 2004;46(2):141-147PubMedArticle
31.
Harada K, Inoue K, Morikawa A, Yoshinaga T, Saito N, Koizumi A. Renal clearance of perfluorooctane sulfonate and perfluorooctanoate in humans and their species-specific excretion.  Environ Res. 2005;99(2):253-261PubMedArticle
32.
Schecter A, Colacino J, Haffner D,  et al.  Perfluorinated compounds, polychlorinated biphenyls, and organochlorine pesticide contamination in composite food samples from Dallas, Texas, USA.  Environ Health Perspect. 2010;118(6):796-802PubMedArticle
33.
Fernández Freire P, Pérez Martin JM, Herrero O, Peropadre A, de la Peña E, Hazen MJ. In vitro assessment of the cytotoxic and mutagenic potential of perfluorooctanoic acid.  Toxicol In Vitro. 2008;22(5):1228-1233PubMedArticle
34.
Liu C, Yu K, Shi X,  et al.  Induction of oxidative stress and apoptosis by PFOS and PFOA in primary cultured hepatocytes of freshwater tilapia (Oreochromis niloticus).  Aquat Toxicol. 2007;82(2):135-143PubMedArticle
35.
Yao X, Zhong L. Genotoxic risk and oxidative DNA damage in HepG2 cells exposed to perfluorooctanoic acid.  Mutat Res. 2005;587(1-2):38-44PubMedArticle
36.
Hu W, Jones PD, DeCoen W,  et al.  Alterations in cell membrane properties caused by perfluorinated compounds.  Comp Biochem Physiol C Toxicol Pharmacol. 2003;135(1):77-88PubMedArticle
37.
Qian Y, Ducatman A, Ward R,  et al.  Perfluorooctane sulfonate (PFOS) induces reactive oxygen species (ROS) production in human microvascular endothelial cells: role in endothelial permeability.  J Toxicol Environ Health A. 2010;73(12):819-836PubMedArticle
38.
Crist BL, Alekel DL, Ritland LM, Hanson LN, Genschel U, Reddy MB. Association of oxidative stress, iron, and centralized fat mass in healthy postmenopausal women.  J Womens Health (Larchmt). 2009;18(6):795-801PubMedArticle
39.
Hanson M, Gluckman P. Endothelial dysfunction and cardiovascular disease: the role of predictive adaptive responses.  Heart. 2005;91(7):864-866PubMedArticle
40.
Harrison DG, Gongora MC. Oxidative stress and hypertension.  Med Clin North Am. 2009;93(3):621-635PubMedArticle
41.
Kudo N, Mizuguchi H, Yamamoto A, Kawashima Y. Alterations by perfluorooctanoic acid of glycerolipid metabolism in rat liver.  Chem Biol Interact. 1999;118(1):69-83PubMedArticle
42.
Van Rafelghem MJ, Vanden Heuvel JP, Menahan LA, Peterson RE. Perfluorodecanoic acid and lipid metabolism in the rat.  Lipids. 1988;23(7):671-678PubMedArticle
43.
Kudo N, Kawashima Y. Induction of triglyceride accumulation in the liver of rats by perfluorinated fatty acids with different carbon chain lengths: comparison with induction of peroxisomal beta-oxidation.  Biol Pharm Bull. 2003;26(1):47-51PubMedArticle
44.
DeWitt JC, Shnyra A, Badr MZ,  et al.  Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha.  Crit Rev Toxicol. 2009;39(1):76-94PubMedArticle
45.
Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.  Circ Res. 2004;94(9):1168-1178PubMedArticle
46.
Frisbee SJ, Shankar A, Knox SS,  et al.  Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents: results from the C8 Health Project.  Arch Pediatr Adolesc Med. 2010;164(9):860-869PubMedArticle
47.
Knox SS, Jackson T, Javins B, Frisbee SJ, Shankar A, Ducatman AM. Implications of early menopause in women exposed to perfluorocarbons.  J Clin Endocrinol Metab. 2011;96(6):1747-1753PubMedArticle
48.
de Kleijn MJ, van der Schouw YT, Verbeek AL, Peeters PH, Banga JD, van der Graaf Y. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women.  Am J Epidemiol. 2002;155(4):339-345PubMedArticle
49.
Lin CY, Lin LY, Chiang CK,  et al.  Investigation of the associations between low-dose serum perfluorinated chemicals and liver enzymes in US adults.  Am J Gastroenterol. 2010;105(6):1354-1363PubMedArticle
50.
Lee DH, Silventoinen K, Hu G,  et al.  Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women.  Eur Heart J. 2006;27(18):2170-2176PubMedArticle
51.
Shankar A, Li J, Klein BE, Javier Nieto F, Klein R. Serum gamma-glutamyltransferase level and peripheral arterial disease.  Atherosclerosis. 2008;199(1):102-109PubMedArticle
52.
Melzer D, Rice N, Depledge MH, Henley WE, Galloway TS. Association between serum perfluorooctanoic acid (PFOA) and thyroid disease in the U.S. National Health and Nutrition Examination Survey.  Environ Health Perspect. 2010;118(5):686-692PubMedArticle
53.
Ochs N, Auer R, Bauer DC,  et al.  Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality.  Ann Intern Med. 2008;148(11):832-845PubMed
54.
Anderson-Mahoney P, Kotlerman J, Takhar H, Gray D, Dahlgren J. Self-reported health effects among community residents exposed to perfluorooctanoate.  New Solut. 2008;18(2):129-143PubMedArticle
55.
Lundin JI, Alexander BH, Olsen GW, Church TR. Ammonium perfluorooctanoate production and occupational mortality.  Epidemiology. 2009;20(6):921-928PubMedArticle
56.
Genuis SJ, Birkholz D, Ralitsch M, Thibault N. Human detoxification of perfluorinated compounds.  Public Health. 2010;124(7):367-375PubMedArticle
Original Investigation
Oct 8, 2012

Perfluorooctanoic Acid and Cardiovascular Disease in US Adults

Author Affiliations

Author Affiliations: Department of Epidemiology, West Virginia University School of Public Health, Morgantown.

Arch Intern Med. 2012;172(18):1397-1403. doi:10.1001/archinternmed.2012.3393
Abstract

Background Cardiovascular disease (CVD) is a major public health problem. Identifying novel risk factors for CVD, including widely prevalent environmental exposures, is therefore important. Perfluorooctanoic acid (PFOA) is a manmade chemical used in the manufacture of common household consumer products. Biomonitoring surveys have shown that PFOA is detectable in the blood of more than 98% of the US population. Experimental animal studies suggest that an association between PFOA and CVD is plausible. However, this association in humans has not been previously examined. We therefore examined the independent relationship between serum PFOA levels and CVD outcomes in a representative sample of Americans.

Methods We examined 1216 subjects (51.2% women) from the 1999-2003 National Health and Nutritional Examination Survey. Serum PFOA levels were examined in quartiles. The main outcomes of interest were self-reported CVD, including coronary heart disease and stroke, and objectively measured peripheral arterial disease (PAD), defined as an ankle-brachial blood pressure index of less than 0.9.

Results We found that increasing serum PFOA levels are positively associated with CVD and PAD, independent of confounders such as age, sex, race/ethnicity, smoking status, body mass index, diabetes mellitus, hypertension, and serum cholesterol level. Compared with quartile 1 (reference) of PFOA level, the multivariable odds ratio (95% CI) among subjects in quartile 4 was 2.01 (1.12-3.60; P = .01 for trend) for CVD and 1.78 (1.03-3.08; P = .04 for trend) for PAD.

Conclusion Exposure to PFOA is associated with CVD and PAD, independent of traditional cardiovascular risk factors.

Human exposure to perfluorooctanoic acid (PFOA) and other perfluoroalkyl chemicals (PFCs) has raised concern because these chemicals are persistent in the environment, bioaccumulated, and biomagnified along food chains and have been shown to cause developmental and other adverse health effects in laboratory animals.13 Perfluorooctanoic acid has been widely used in the manufacture of industrial and consumer products such as surfactants, lubricants, polishes, paper and textile coatings, food packaging, and fire-retarding foams.3 In addition, PFOA has been detected in the blood of more than 98% of Americans.4 Recent evidence from retired employees in PFOA production facilities suggest a relatively long elimination half-life of approximately 3.8 years for PFOA.5

Cardiovascular disease (CVD) is the leading cause of death in the United States.6 Approximately 70% of CVD can be attributed to modifiable, nongenetic factors,7 and classic risk factors, such as smoking status and obesity, among others, do not account for all the observed CVD risk in the general population.8,9 Recent studies have suggested that common environmental exposures affecting large sections of the population may be a determinant of CVD risk.10,11 Because virtually all US adults have detectable blood levels of PFCs, an intriguing hypothesis is that exposure to PFCs may be associated with a higher risk of developing CVD.

Several lines of recent evidence suggest that an association between PFOA exposure and CVD may be biologically plausible. In epidemiological studies in humans, PFOA exposure has been linked to higher cholesterol levels,1216 which represent a strong, independent risk factor for CVD development.17 Higher PFOA levels were shown to be related to insulin resistance and metabolic syndrome in a recent epidemiological study in adolescents and adults.18 Insulin resistance and components of the metabolic syndrome have previously been shown to be associated with CVD development in epidemiological studies.19 Finally, we have recently shown that higher PFOA levels are associated with serum uric acid levels,20 a marker shown to be associated with an increased risk of developing CVD in epidemiological studies.21 Despite these leads, to our knowledge, no previous study has examined the putative association between PFOA and CVD. We therefore examined the independent association between serum levels of PFOA and the presence of CVD and peripheral arterial disease (PAD), a marker of atherosclerosis, in a contemporary, nationally representative sample of US adults.

METHODS

The present study is based on merged data from the 1999-2000 and 2003-2004 National Health and Nutrition Examination Survey (NHANES). A detailed description of the NHANES study design and methods are available elsewhere.22 In brief, the NHANES population included a stratified, multistage probability sample representative of the civilian noninstitutionalized US population. Selection was based on counties, blocks, households, and individuals within households and included the oversampling of low-income persons, persons 60 years or older, and African American and Mexican American persons to provide stable estimates of these groups. The survey included biomonitoring of PFC levels by the National Center for Environmental Health in a random one-third subsample of participants.

The present study sample consisted of 1327 NHANES participants 40 years or older who had measurements of PFOA levels and ankle-brachial index blood pressure (ABI) available. We excluded subjects with missing data (n = 111) on covariates included in the multivariable model, such as educational level, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), or cholesterol levels. The final sample consisted of 1216 participants (51.2% women).

MAIN OUTCOMES: CVD AND PAD

Participants were asked, “Has a doctor or other health professional ever told you that you have. . . . ” in separate questions for coronary heart disease and stroke. The study defined CVD as physician-diagnosed coronary heart disease, heart attack, or stroke.23

We defined PAD in the present study using ABI. Details of methods used to measure ABI in NHANES have been described previously.24 In brief, supine systolic blood pressure was measured with blood pressure cuffs on the right arm compressing the brachial artery and the 2 posterior tibial arteries. For subjects aged 40 to 59 years, 2 measurements were taken at each site and averaged per site, whereas for participants 60 years or older, one measurement was taken at each site. We calculated ABI as the ratio of the average ankle systolic blood pressure to the average arm systolic blood pressure. Participants with an ABI of at least 1.5 may have severe arterial rigidity and were therefore excluded from all analyses (n = 4). For the present study, PAD was defined as an ABI of less than 0.9, consistent with current guidelines25 and national reports24 using NHANES data. The weighted prevalences of the outcomes used in the present analyses were CVD, 13.0%; PAD, 4.5%; and CVD or PAD, 16.6%.

EXPOSURE MEASUREMENTS

Age, sex, race/ethnicity, smoking status, alcohol intake, level of education, and medication use were assessed using a questionnaire. Rigorous procedures with quality control checks were used in blood collection, and details of these procedures are provided in the NHANES Laboratory/Medical Technologists Procedures Manual.26 Levels of PFOA were measured in serum by the National Center for Environmental Health using automated solid-phase extraction coupled to isotope-dilution high-performance liquid chromatography–tandem mass spectrometry.4 Perfluorooctanoic acid was detected in more than 98% of the study population. Values less than the limit of detection were reported by NHANES as the limit of detection divided by the square root of 2. The limit of detection for PFOA was 0.1 ng/mL, and the interassay coefficient of variation was 11%.4

Serum total cholesterol levels were measured enzymatically. Serum glucose levels were measured using the modified hexokinase method. Diabetes mellitus was defined based on the guidelines of the American Diabetes Association.27 Seated systolic and diastolic blood pressures were measured using a mercury sphygmomanometer, and hypertension was defined according to the Seventh Joint National Committee recommendations.28

STATISTICAL ANALYSIS

We were interested in studying the association between increasing PFOA exposure and the presence of vascular disease. We initially performed separate analyses for the presence of CVD, PAD, and CVD or PAD as our 3 outcomes. Because results were similar, we are presenting herein the findings for the combined outcome. We categorized serum PFOA levels into quartiles based on sex because sex differences in PFOA levels have been well documented.24,2931 We used multivariable logistic regression models to calculate the odds ratio (OR [95% CI]) for the presence of CVD or PAD for each higher PFOA level by taking the lowest category as the reference level. We adjusted for the following variables in the multivariable model: age (in years), sex (men or women), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, or other), educational level (<high school, high school, or >high school), smoking status (never, former, or current), alcohol intake (none, moderate, or heavy), BMI, diabetes mellitus (absent or present), hypertension (absent or present), and serum total cholesterol level (in milligrams per deciliter). Trends in the OR of CVD or PAD across increasing serum PFOA levels were determined by modeling increasing PFOA categories as an ordinal variable. We examined the consistency of the association between serum PFOA and the presence of CVD or PAD by performing stratified analysis by sex, BMI, and smoking status. Sample weights that account for the unequal probabilities of selection, oversampling, and nonresponse and complex survey design were incorporated as recommended22 in all analyses using commercially available software (SUDAAN, version 8.0 [Research Triangle Institute] and SAS, version 9.2 [SAS Institute, Inc]). We calculated SEs using the Taylor series linearization method.

RESULTS

Table 1 presents the baseline characteristics of the study population. Subjects with higher PFOA levels were more likely to be younger, non-Hispanic white, and heavy drinkers; were more likely to have education beyond high school, hypertension, and higher total cholesterol levels; and were less likely to be non-Hispanic black or Mexican American. Compared with subjects who were included in the final study sample, those who were excluded owing to missing covariate data were significantly younger but were similar with respect to other demographic and lifestyle characteristics listed in Table 1 (data not presented).

Table 2 presents the results of analyses examining the association between increasing serum levels of PFOA and the presence of CVD or PAD. Overall, we found that increasing levels of PFOA were significantly associated with CVD and PAD in the multivariable-adjusted model. Models evaluating trend in this association were also statistically significant.

In separate analyses, we also examined the association between increasing levels of PFOA and components of CVD, including coronary heart disease and stroke (see eTable 1). Compared with subjects in quartile 1 of PFOA levels, the multivariable-adjusted OR (95% CI) in quartile 4 was 2.24 (1.02-4.94) for the presence of coronary heart disease and 4.26 (1.84-9.89) for the presence of stroke.

Tables 3, 4, and 5 present the association between increasing serum levels of PFOA and the presence of CVD or PAD within subgroups of sex, smoking status, and BMI, respectively. Overall, consistent with the findings for the whole cohort, we found that higher PFOA levels were associated with the presence of CVD or PAD within these stratified subgroups also (P > .10 for interaction in all subgroup analyses). However, some of the ORs failed to reach conventional levels of statistical significance owing to reduction in sample size and therefore inadequate statistical power within categories.

Finally, in a supplementary analysis, we examined the association between increasing quartiles of PFOA level and the presence of CVD or PAD with additional adjustments for serum high-sensitivity C-reactive protein and serum uric acid levels (see eTable 2) in the multivariable-adjusted model; the overall results were essentially the same, although the ORs were slightly attenuated.

COMMENT

In a nationally representative sample of US adults, we found that higher PFOA levels were positively associated with the presence of CVD and PAD. This association appeared to be independent of traditional confounders such as age, sex, race/ethnicity, smoking status, heavy alcohol intake, BMI, diabetes mellitus, hypertension, and serum cholesterol level. In subgroup analyses, we found that higher PFOA levels were positively associated with CVD or PAD in men as well as women, nonobese as well as obese subjects, and nonsmokers as well as current smokers. Our results contribute to the emerging data12,13,20 on health effects of PFCs, suggesting for the first time that PFOA exposure is potentially related to CVD and PAD. However, owing to the cross-sectional nature of the present study, we cannot conclude that the association is causal.

Perfluorooctanoic acid belongs to a family of synthetic, highly stable, perfluorinated compounds.13 The chemical is widely used in industrial and consumer products, including stain- and water-resistant coatings for carpets and fabrics, fast-food contact materials, food packaging, fire-resistant foams, paints, and hydraulic fluids.1,3 Additional sources of PFOA exposure to humans are through drinking water, outdoor and indoor air, dust, and food packaging.3 Recently, Schecter et al32 showed that commonly consumed meat, fish, and plant products in US supermarkets are contaminated by PFOA. General population studies have shown that in addition to the near-ubiquitous presence of PFOA in blood of Americans, the chemical may also be present in breast milk, seminal fluid, and umbilical cord blood.2 Perfluorooctanoic acid binds to serum proteins and has a relatively long half-life.5 The carbon-fluoride bonds that make PFOA useful as a surfactant are highly stable, which also makes the chemical resistant to biogradation; consequently, recent reports indicate the widespread persistence of PFOA in the environment and in wildlife and human populations globally.1,2 Owing to the pervasive presence of PFOA, its public health effects are a concern.

Several lines of recent evidence suggest that an association between PFOA and the presence of CVD and PAD may be plausible. First, in vitro studies suggest that exposure to PFOA is associated with higher oxidative stress3335 and endothelial dysfunction.36,37 Higher oxidative stress and endothelial dysfunction in turn are considered to be mechanisms involved in atherosclerosis and CVD development.3840 Second, exposure to PFOA has been associated with marked accumulation of triglycerides and lipids in the liver of rats41,42 and induction of peroxisomal α- and β-oxidation.43 Studies in animal models suggest that PFOA adversely affects the peroxisome proliferator-activated receptor α and related inflammatory pathways,44 thereby potentially contributing to the development of CVD.45 Third, in humans, serum PFOA levels have been found to be positively associated with serum cholesterol levels in several occupational studies1416 and 1 community-based study.13 Recently, in the C8 Health Project, a large population-based study of community residents from Ohio and West Virginia who were exposed to PFOA through their drinking water, the authors showed that serum levels of PFOA are independently associated with high serum total and low-density lipoprotein cholesterol levels in adults12 and in children and adolescents.46 Also, Olsen and Zobel16 reported a modest negative association between PFOA and serum high-density lipoprotein cholesterol levels and a positive association between PFOA and serum triglyceride levels. In this regard, higher serum total and low-density lipoprotein cholesterol and triglyceride levels and low high-density lipoprotein cholesterol levels are known to be independent risk factors for CVD.17 Fourth, serum PFOA levels have been reported to be positively associated with insulin resistance13 and components of the metabolic syndrome,18 factors that have been shown to be associated with CVD development.19 Sixth, PFOA exposure has been found to be significantly associated with elevated serum uric acid levels in a previous cross-sectional study of 1000 workers at a PFOA production plant.14 Using data from the C8 Health Project, we also recently reported that PFOA levels were independently associated with high serum uric acid levels.20 Several studies have in turn shown that higher serum uric acid levels are related to increased risk of CVD and CVD mortality.21 Seventh, again using data from the C8 Health Project, we recently reported an inverse association between serum PFOA and estradiol levels in women.47 Decreased serum estrogen levels have been reported to be associated with higher risk of CVD.48 Eighth, recent studies have reported a positive association between serum levels of PFOA and γ-glutamyltransferase,49 another biomarker related to liver function and oxidative stress that has been shown to independently predict CVD50 and PAD.51 Ninth, recent reports from NHANES suggest that PFOA levels are related to thyroid dysfunction,52 a factor that has been reported to be associated with CVD.53

To date, only 3 studies have been conducted on the putative association between higher PFOA levels and CVD, and their results have not been consistent.52,54,55 In a population of 566 white community residents exposed to PFOA via drinking water, Anderson-Mahoney et al54 reported a statistically significant higher age-adjusted (via indirect standardization) prevalence of self-reported angina, myocardial infarction, and stroke compared with controls selected from NHANES data. Similarly, in an occupational cohort of employees from a PFOA manufacturing facility, Lundin et al55 reported a positive, albeit statistically nonsignificant, trend of stroke mortality across nonexposed, probably exposed, and definitely exposed job categories using indirect standardization. However, both studies performed only indirect age standardization and did not account for other important confounders, such as smoking status, BMI, diabetes mellitus, hypertension, or serum cholesterol levels. In contrast, Melzer et al52 examined data from the NHANES study and reported no significant association between PFOA levels and self-reported CVD. The latter study, however, did not adjust for important confounding factors, such as diabetes, hypertension, or serum cholesterol levels, and the authors examined only self-reported CVD, which is prone to misclassification, as opposed to objectively measured outcome measures.

In this context, our results from a contemporary, nationally representative sample of US adults are relevant. We found an independent association between serum PFOA levels and the presence of self-reported CVD and objectively measured PAD. The observed associations were found to be independent of confounders, such as age, sex, smoking status, BMI, diabetes mellitus, hypertension, and serum cholesterol, serum uric acid, and serum high-sensitivity C-reactive protein levels, and consistently present within the subgroups of sex, smoking status, and BMI, suggesting that these findings are not likely to be due to chance.

The public health importance of our findings is that serum PFOA levels appear to be positively related to these common CVD outcomes even at relatively low, “background” exposure levels in the US general population. Because all PFOA is manmade, this excess risk may be removed or substantially mitigated through regulation or by emerging pharmacological means that need to be further studied (eg, using bile acid sequestrants56). Therefore, if our findings are replicated in future prospective studies, the population-attributable risk of PFOA exposure on CVD risk could potentially be high.

The main strengths of our study include its population-based nature, inclusion of a representative multiethnic sample, adequate sample size, and the availability of detailed data on confounders for multivariable adjustment. Furthermore, all data were collected following rigorous methods, including a study protocol with standardized quality control checks. The main limitation of our study is the cross-sectional nature of NHANES. Therefore, similar to previous studies that examined the association between other environmental exposures and disease states using the NHANES data (eg, bisphenol A levels and CVD23), the temporal nature of the association between PFOA and CVD cannot be concluded from the present study. Second, our study does not have the data to estimate the sources of exposure to PFOA. Future studies should examine sources of PFOA in addition to serum levels for identifying preventive measures to limit exposure. Third, the pharmacokinetics of PFOA in humans have not yet been completely elucidated; studies available to date have reported a wide range of values for serum half-life. Accurate identification of half-life is important to interpret the observed association of serum PFOA levels to CVD in humans. Fourth, we are examining PFOA levels measured in the serum at just one point. This point may not provide an accurate estimate of the average or the cumulative effect of PFOA exposure across several years; epidemiological studies measuring PFOA levels at multiple points are needed for this purpose. Fifth, owing to the cross-sectional nature of our study, we may have missed subjects who died of CVD, which is our main outcome. Finally, because CVD was ascertained by self-report, some recollection bias may exist. These last two study limitations may have resulted in outcome misclassification that in turn may have biased our results toward or away from the null.

In summary, in a representative cross-sectional sample of the US population, we found that higher PFOA levels are positively associated with self-reported CVD and objectively measured PAD. Our findings, however, should be interpreted with caution because of the possibility of residual confounding and reverse causality. Future prospective studies are needed to confirm or refute our findings.

Back to top
Article Information

Correspondence: Anoop Shankar, MD, PhD, Department of Epidemiology, West Virginia University School of Public Health, 1 Medical Center Dr, PO Box 9190, Morgantown, WV 26506 (ashankar@hsc.wvu.edu).

Accepted for Publication: May 27, 2012.

Published Online: September 3, 2012. doi:10.1001/archinternmed.2012.3393

Author Contributions:Study concept and design: Shankar and Ducatman. Acquisition of data: Shankar. Analysis and interpretation of data: Shankar, Xiao, and Ducatman. Drafting of the manuscript: Shankar. Critical revision of the manuscript for important intellectual content: Shankar, Xiao, and Ducatman. Statistical analysis: Shankar and Xiao. Obtained funding: Shankar. Administrative, technical, and material support: Shankar and Ducatman.

Financial Disclosure: None reported.

Funding/Support: This study was supported by a National Clinical Research Program grant from the American Heart Association (Dr Shankar) and grants R01 ES021825-01 and 5R03ES018888-02 from the National Institute of Environmental Health Sciences, National Institutes of Health (Dr Shankar).

REFERENCES
1.
US Environmental Protection Agency.  Perfluorooctanoic acid (PFOA) and fluorinated telomers. http://www.epa.gov/oppt/pfoa/. Accessed May 5, 2010
2.
Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. Perfluoroalkyl acids: a review of monitoring and toxicological findings.  Toxicol Sci. 2007;99(2):366-394PubMedArticle
3.
Cui L, Zhou QF, Liao CY, Fu JJ, Jiang GB. Studies on the toxicological effects of PFOA and PFOS on rats using histological observation and chemical analysis.  Arch Environ Contam Toxicol. 2009;56(2):338-349PubMedArticle
4.
Calafat AM, Wong LY, Kuklenyik Z, Reidy JA, Needham LL. Polyfluoroalkyl chemicals in the US population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000.  Environ Health Perspect. 2007;115(11):1596-1602PubMedArticle
5.
Olsen GW, Burris JM, Ehresman DJ,  et al.  Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers.  Environ Health Perspect. 2007;115(9):1298-1305PubMedArticle
6.
Levy RI, Moskowitz J. Cardiovascular research: decades of progress, a decade of promise.  Science. 1982;217(4555):121-129PubMedArticle
7.
Willett WC. Balancing life-style and genomics research for disease prevention.  Science. 2002;296(5568):695-698PubMedArticle
8.
Grundy SM, D’Agostino RB Sr, Mosca L,  et al.  Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood Institute workshop.  Circulation. 2001;104(4):491-496PubMedArticle
9.
Nieto FJ. Cardiovascular disease and risk factor epidemiology: a look back at the epidemic of the 20th century.  Am J Public Health. 1999;89(3):292-294PubMedArticle
10.
Bhatnagar A. Environmental cardiology: studying mechanistic links between pollution and heart disease.  Circ Res. 2006;99(7):692-705PubMedArticle
11.
Taylor AE. Cardiovascular effects of environmental chemicals.  Otolaryngol Head Neck Surg. 1996;114(2):209-211PubMedArticle
12.
Steenland K, Tinker S, Frisbee S, Ducatman A, Vaccarino V. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant.  Am J Epidemiol. 2009;170(10):1268-1278PubMedArticle
13.
Nelson JW, Hatch EE, Webster TF. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general US population.  Environ Health Perspect. 2010;118(2):197-202PubMedArticle
14.
Sakr CJ, Kreckmann KH, Green JW, Gillies PJ, Reynolds JL, Leonard RC. Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers.  J Occup Environ Med. 2007;49(10):1086-1096PubMedArticle
15.
Sakr CJ, Leonard RC, Kreckmann KH, Slade MD, Cullen MR. Longitudinal study of serum lipids and liver enzymes in workers with occupational exposure to ammonium perfluorooctanoate.  J Occup Environ Med. 2007;49(8):872-879PubMedArticle
16.
Olsen GW, Zobel LR. Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers.  Int Arch Occup Environ Health. 2007;81(2):231-246PubMedArticle
17.
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories.  Circulation. 1998;97(18):1837-1847PubMedArticle
18.
Lin CY, Chen PC, Lin YC, Lin LY. Association among serum perfluoroalkyl chemicals, glucose homeostasis, and metabolic syndrome in adolescents and adults.  Diabetes Care. 2009;32(4):702-707PubMedArticle
19.
Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study.  J Am Coll Cardiol. 2007;49(21):2112-2119PubMedArticle
20.
Steenland K, Tinker S, Shankar A, Ducatman A. Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with uric acid among adults with elevated community exposure to PFOA.  Environ Health Perspect. 2010;118(2):229-233PubMedArticle
21.
Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992.  JAMA. 2000;283(18):2404-2410PubMedArticle
22.
National Center for Health Statistics.  National Health and Nutrition Examination Survey: reference manuals and reports. http://www.cdc.gov/nchs/nhanes/nhanes2003-2004/nhanes03_04.htm. Accessed May 5, 2010
23.
Lang IA, Galloway TS, Scarlett A,  et al.  Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults.  JAMA. 2008;300(11):1303-1310PubMedArticle
24.
Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.  Circulation. 2004;110(6):738-743PubMedArticle
25.
American Diabetes Association.  Peripheral arterial disease in people with diabetes.  Diabetes Care. 2003;26(12):3333-3341PubMedArticle
26.
National Center for Health Statistics CfDC.  Laboratory procedure manual for serum creatinine. http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/l40_c_met_creatinine.pdf. Accessed May 6, 2010
27.
American Diabetes Association.  Diagnosis and classification of diabetes mellitus.  Diabetes Care. 2012;35:(suppl 1)  S64-S71PubMedArticle
28.
Chobanian AV, Bakris GL, Black HR,  et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.  Hypertension. 2003;42(6):1206-1252PubMedArticle
29.
Hanhijärvi H, Ophaug RH, Singer L. The sex-related difference in perfluorooctanoate excretion in the rat.  Proc Soc Exp Biol Med. 1982;171(1):50-55PubMed
30.
Harada K, Saito N, Inoue K,  et al.  The influence of time, sex and geographic factors on levels of perfluorooctane sulfonate and perfluorooctanoate in human serum over the last 25 years.  J Occup Health. 2004;46(2):141-147PubMedArticle
31.
Harada K, Inoue K, Morikawa A, Yoshinaga T, Saito N, Koizumi A. Renal clearance of perfluorooctane sulfonate and perfluorooctanoate in humans and their species-specific excretion.  Environ Res. 2005;99(2):253-261PubMedArticle
32.
Schecter A, Colacino J, Haffner D,  et al.  Perfluorinated compounds, polychlorinated biphenyls, and organochlorine pesticide contamination in composite food samples from Dallas, Texas, USA.  Environ Health Perspect. 2010;118(6):796-802PubMedArticle
33.
Fernández Freire P, Pérez Martin JM, Herrero O, Peropadre A, de la Peña E, Hazen MJ. In vitro assessment of the cytotoxic and mutagenic potential of perfluorooctanoic acid.  Toxicol In Vitro. 2008;22(5):1228-1233PubMedArticle
34.
Liu C, Yu K, Shi X,  et al.  Induction of oxidative stress and apoptosis by PFOS and PFOA in primary cultured hepatocytes of freshwater tilapia (Oreochromis niloticus).  Aquat Toxicol. 2007;82(2):135-143PubMedArticle
35.
Yao X, Zhong L. Genotoxic risk and oxidative DNA damage in HepG2 cells exposed to perfluorooctanoic acid.  Mutat Res. 2005;587(1-2):38-44PubMedArticle
36.
Hu W, Jones PD, DeCoen W,  et al.  Alterations in cell membrane properties caused by perfluorinated compounds.  Comp Biochem Physiol C Toxicol Pharmacol. 2003;135(1):77-88PubMedArticle
37.
Qian Y, Ducatman A, Ward R,  et al.  Perfluorooctane sulfonate (PFOS) induces reactive oxygen species (ROS) production in human microvascular endothelial cells: role in endothelial permeability.  J Toxicol Environ Health A. 2010;73(12):819-836PubMedArticle
38.
Crist BL, Alekel DL, Ritland LM, Hanson LN, Genschel U, Reddy MB. Association of oxidative stress, iron, and centralized fat mass in healthy postmenopausal women.  J Womens Health (Larchmt). 2009;18(6):795-801PubMedArticle
39.
Hanson M, Gluckman P. Endothelial dysfunction and cardiovascular disease: the role of predictive adaptive responses.  Heart. 2005;91(7):864-866PubMedArticle
40.
Harrison DG, Gongora MC. Oxidative stress and hypertension.  Med Clin North Am. 2009;93(3):621-635PubMedArticle
41.
Kudo N, Mizuguchi H, Yamamoto A, Kawashima Y. Alterations by perfluorooctanoic acid of glycerolipid metabolism in rat liver.  Chem Biol Interact. 1999;118(1):69-83PubMedArticle
42.
Van Rafelghem MJ, Vanden Heuvel JP, Menahan LA, Peterson RE. Perfluorodecanoic acid and lipid metabolism in the rat.  Lipids. 1988;23(7):671-678PubMedArticle
43.
Kudo N, Kawashima Y. Induction of triglyceride accumulation in the liver of rats by perfluorinated fatty acids with different carbon chain lengths: comparison with induction of peroxisomal beta-oxidation.  Biol Pharm Bull. 2003;26(1):47-51PubMedArticle
44.
DeWitt JC, Shnyra A, Badr MZ,  et al.  Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha.  Crit Rev Toxicol. 2009;39(1):76-94PubMedArticle
45.
Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.  Circ Res. 2004;94(9):1168-1178PubMedArticle
46.
Frisbee SJ, Shankar A, Knox SS,  et al.  Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents: results from the C8 Health Project.  Arch Pediatr Adolesc Med. 2010;164(9):860-869PubMedArticle
47.
Knox SS, Jackson T, Javins B, Frisbee SJ, Shankar A, Ducatman AM. Implications of early menopause in women exposed to perfluorocarbons.  J Clin Endocrinol Metab. 2011;96(6):1747-1753PubMedArticle
48.
de Kleijn MJ, van der Schouw YT, Verbeek AL, Peeters PH, Banga JD, van der Graaf Y. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women.  Am J Epidemiol. 2002;155(4):339-345PubMedArticle
49.
Lin CY, Lin LY, Chiang CK,  et al.  Investigation of the associations between low-dose serum perfluorinated chemicals and liver enzymes in US adults.  Am J Gastroenterol. 2010;105(6):1354-1363PubMedArticle
50.
Lee DH, Silventoinen K, Hu G,  et al.  Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women.  Eur Heart J. 2006;27(18):2170-2176PubMedArticle
51.
Shankar A, Li J, Klein BE, Javier Nieto F, Klein R. Serum gamma-glutamyltransferase level and peripheral arterial disease.  Atherosclerosis. 2008;199(1):102-109PubMedArticle
52.
Melzer D, Rice N, Depledge MH, Henley WE, Galloway TS. Association between serum perfluorooctanoic acid (PFOA) and thyroid disease in the U.S. National Health and Nutrition Examination Survey.  Environ Health Perspect. 2010;118(5):686-692PubMedArticle
53.
Ochs N, Auer R, Bauer DC,  et al.  Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality.  Ann Intern Med. 2008;148(11):832-845PubMed
54.
Anderson-Mahoney P, Kotlerman J, Takhar H, Gray D, Dahlgren J. Self-reported health effects among community residents exposed to perfluorooctanoate.  New Solut. 2008;18(2):129-143PubMedArticle
55.
Lundin JI, Alexander BH, Olsen GW, Church TR. Ammonium perfluorooctanoate production and occupational mortality.  Epidemiology. 2009;20(6):921-928PubMedArticle
56.
Genuis SJ, Birkholz D, Ralitsch M, Thibault N. Human detoxification of perfluorinated compounds.  Public Health. 2010;124(7):367-375PubMedArticle
×